For its fourth fiscal quarter (ending December 31), Ligand Pharmaceuticals Inc (NASDAQ: LGND) has reported E.P.S. of $1.04 compared to $-0.86 a year ago. This performance was $0.38 better than the consensus estimate of $0.66. E.P.S. were $3.11 for the latest four quarters through December 31 versus $-0.31 for the same period a year ago.
Recent Price Action
On 2/27/24, Ligand Pharmaceuticals Inc (NASDAQ: LGND) stock enjoyed a major increase of 19.9%, closing at $89.20. Moreover, trading volume in this advance was exceptionally high at 666% of normal. The stock has performed in line with the market over the last nine months and has risen 21.1% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, LGND is expected to continue to be an important Value Builder.
Ligand Pharmaceuticals has a current Value Trend Rating of D (Negative). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Ligand Pharmaceuticals has a poor Appreciation Score of 22 but a neutral Power Rating of 53, producing the Negative Value Trend Rating.
Rating Review
In light of this new information and very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment